Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.69 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.69 |
| ▸ | KMO | O15229 | 2/20 | 0.57 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DDO | Q99489 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181717 | 0.89 | MKNK1 (0.69) | MKNK1MKNK2KMOXDHHCAR2 | |
| SCHEMBL28814001 | 0.88 | MKNK1 (0.61) | MKNK1MKNK2KMOKAT6AXDH | |
| SCHEMBL1690466 | 0.87 | KMO (0.75) | MKNK1MKNK2KMOHCAR2POLB | |
| SCHEMBL1132812 | 0.87 | KMO (0.79) | MKNK1MKNK2KMOLMNADHODH | |
| SCHEMBL28392499 | 0.86 | MKNK1 (0.67) | MKNK1MKNK2KMOXDHHCAR2 | |
| SCHEMBL10028681 | 0.85 | KMO (0.73) | MKNK1MKNK2KMOHCAR2ALDH1A1 | |
| SCHEMBL24499959 | 0.85 | MKNK1 (0.57) | MKNK1MKNK2KMOKAT6AXDH | |
| SCHEMBL2488476 | 0.85 | MKNK1 (0.77) | MKNK1MKNK2KAT6ADHODHMAP4K4 | |
| SCHEMBL1652519 | 0.85 | MKNK2 (0.68) | MKNK1MKNK2KAT6AXDHSCN2A | |
| SCHEMBL15265103 | 0.84 | CHEK1 (0.64) | MKNK1MKNK2KMOKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025151311-A1 | NICOTINAMIDE DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-4540226-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-04-23 | — | — | EP | disclosed |
| CN-119384408-A | Bifunctional molecules for targeted protein degradation | 安菲斯塔治疗有限责任公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240124431-A1 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | ORION CORPORATION (FI) | 2024-04-18 | — | — | US | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023242597-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| CN-1146542-C | Benzamide derivatives and their use as cytokine inhibitors | — | 2004-04-21 | — | — | CN | disclosed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | disclosed |
| CN-1319092-A | Benzamide derivatives and their use as cytokine inhibitors | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | CN | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0180794-B1 | PYRIDINE DERIVATIVES | MERCK PATENT GmbH (DE) | 1989-05-31 | — | — | EP | disclosed |
| US-4760082-A | Certain di-aryl-1,2,3,6-tetrahydro-pyridyl-n-lower-alkylene-pyridines having neuroleptic properties | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-07-26 | — | — | US | disclosed |
| US-4665187-A | Certain 1,2,3,6-tetrahydro-pyridyl-N-lower-alkanoyl-pyridines as intermediates | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-05-12 | — | — | US | disclosed |
| EP-0180794-A1 | Pyridine derivatives | MERCK PATENT GmbH (DE) | 1986-05-14 | — | — | EP | disclosed |
| US-4473395-A | Method for inducing tillering utilizing certain pyridine-1-oxides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | MKNK1 2249/4885MKNK2 2522/4885KMO 4357/4885 |
| US-20240124431-A1 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | CYP11B1, CYP11B2, SRD5A1 | MKNK1 3488/4885MKNK2 3505/4885KMO 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.